A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Latest Information Update: 29 Apr 2025
At a glance
- Drugs VENT 02 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Ventus Therapeutics
Most Recent Events
- 25 Feb 2025 Status changed from not yet recruiting to recruiting.
- 13 Feb 2025 Status changed to not yet recruiting.
- 19 Apr 2024 New trial record